FROM MOLECULE...TO HUMAN
To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
All the news of the Institute of life sciences Frédéric Joliot
Scientific result | Vaccine
Researchers from Pasteur Institute, in collaboration with seven research teams, including SPI (LI2D/Marcoule), developed and evaluated the efficacy of several vaccine candidates against the virus responsible for Lassa haemorrhagic fever, endemic in Western Africa. They identified one of them as being the most effective, likely to quickly enter clinical trials in humans. Results are published in the journal Science Translational Medicine.
Lassa fever is a major threat in Western Africa. The large number of people living at risk for this disease calls for the development of a vaccine against Lassa virus (LASV). We generated live-attenuated LASV vaccines based on measles virus and Mopeia virus platforms and expressing different LASV antigens, with the aim to develop a vaccine able to protect after a single shot. We compared the efficacy of these vaccines against LASV in cynomolgus monkeys. The vaccines were well tolerated and protected the animals from LASV infection and disease after a single immunization but with varying efficacy. Analysis of the immune responses showed that complete protection was associated with robust secondary T cell and antibody responses against LASV. Transcriptomic and proteomic analyses showed an early activation of innate immunity and T cell priming after immunization with the most effective vaccines, with changes detectable as early as 2 days after immunization. The most efficacious vaccine candidate, a measles vector simultaneously expressing LASV glycoprotein and nucleoprotein, has been selected for further clinical evaluation.
M Mateo, S Reynard, X Carnec, A Journeaux, N Baillet, J Schaeffer, C Picard, C Legras-Lachuer, R Allan, E Perthame, KH Hillion, N Pietrosemoli, MA Dillies, L Barrot, A Vallve, S Barron, L Fellmann, JC Gaillard, J Armengaud, C Carbonnelle, H Raoul, F Tangy, S Baize. Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot, Science Translational Medicine, 2 octobre 2019
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.